Company: MBIO
Filing Date: 2025-03-05
Form Type: 8-K
Source: 0001104659-25-020900
Chunk: 0

Company: MUSTANG BIO, INC.
Filing Date: 2025-03-05
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01.      Other Events.  

Nasdaq
Continued Listing Requirements

On March
5, 2025, Mustang Bio, Inc. (the “ Company”) announced that it received formal notice from The Nasdaq Stock Market LLC (“ Nasdaq”)
that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the
minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the “ Equity Rule”). As a result,
the previously disclosed listing compliance matter has been closed.

The Company
was also notified that it will remain subject to a “ Panel Monitor,” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B),
for a period of one year from the date of the Nasdaq notice, through February 26, 2026. If, during the term of the Panel Monitor, the
Company does not satisfy the Equity Rule, the Company will not be provided with the opportunity to submit a compliance plan for review
by the Listing Qualifications Staff and must instead request a hearing before the Nasdaq Hearings Panel to address the deficiency, with
such request staying any further action with respect to the Company’s listing on Nasdaq pending completion of the hearing process.

On March
5, 2025, the Company issued a press release announcing receipt of the compliance determination from Nasdaq. A copy of the press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.